Regeneron Pharmaceuticals Down Over 10%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk

Dow Jones05-18

Regeneron Pharmaceuticals, Inc. $(REGN)$ is currently at $623.96, down $74.29 or 10.64%

 

--Would be lowest close since Oct. 27, 2025, when it closed at $585.31

--On pace for largest percent decrease since May 30, 2025, when it fell 19.01%

--Currently down five of the past six days

--Currently down four consecutive days; down 13.75% over this period

--Longest losing streak since April 29, 2026, when it fell for four straight trading days

--Worst four day stretch since the four days ending June 4, 2025, when it fell 19.9%

--Down 11.75% month-to-date

--Down 19.16% year-to-date

--Down 48.08% from its all-time closing high of $1201.76 on Aug. 27, 2024

--Up 4.6% from 52 weeks ago (May 19, 2025), when it closed at $596.54

--Down 23.18% from its 52-week closing high of $812.27 on Jan. 7, 2026

--Up 29.17% from its 52-week closing low of $483.07 on June 5, 2025

--Traded as low as $610.60; lowest intraday level since Oct. 28, 2025, when it hit $605.03

--Down 12.55% at today's intraday low; largest intraday percent decrease since May 30, 2025, when it fell as much as 19.89%

--Worst performer in the S&P 500 today

--Worst performer in the Nasdaq 100 today

 

All data as of 9:53:19 AM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

May 18, 2026 09:55 ET (13:55 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment